ISRG vs RMD vs SOLV Stock Comparison

Intuitive Surgical, Resmed and Solventum Prices as of Nov 13, 2026 Peers: Industry group
ISRG Intuitive Surgical Inc
$443.59 +5.6% 1M -21.6% 1Y
Market cap
$153.38B
P/E
51.9x
Revenue (TTM)
$11.58B
Div. yield
–
Medical Devices Healthcare
4 wins
RMD Resmed Inc
$239.53 +1.7% 1M -5.0% 1Y
Market cap
$34.22B
P/E
21.5x
Revenue (TTM)
$5.73B
Div. yield
–
Medical Devices Healthcare
4 wins
SOLV Solventum Corp
$89.05 +2.0% 1M +18.4% 1Y
Market cap
$15.18B
P/E
97.3x
Revenue (TTM)
$8.16B
Div. yield
–
Medical Devices Healthcare
3 wins

Head to Head

11 decided of 12

Intuitive Surgical leads on 4 of the 12 questions below (Intuitive Surgical 4, Resmed 4, Solventum 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionISRGRMDSOLVLeader
Larger companyMarket capitalisation $153.38B $34.22B $15.18B ISRG
Cheaper on earningsLower P/E, profitable companies only 51.9x 21.5x 97.3x RMD
Cheaper on forward earningsLower price / next fiscal year consensus EPS 38.5x 18.5x 12.8x SOLV
Faster revenue growthRevenue growth, trailing twelve months +20.5% +9.0% -2.8% ISRG
More profitableNet margin, trailing twelve months 25.5% 27.8% 1.9% RMD
Better return on capitalReturn on invested capital — 22.0% 4.2% RMD
Less leveragedLower net debt / EBITDA — -0.3x 4.7x RMD
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -21.6% -5.0% +18.4% SOLV
Better 5-year returnAnnualised price return, 5 years +4.6%/yr -1.2%/yr — ISRG
Less volatileAnnualised volatility, 1 year 36.1% 31.1% 30.1% SOLV
Higher overall scoreMean of the five percentile scores vs peers 81/100 80/100 51/100 ISRG

Percentile Scorecard

ISRGRMDSOLV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisISRGRMDSOLV
Valuation 52 #118 of 243 75 #62 of 243 70 #74 of 243
Growth 81 #45 of 228 60 #92 of 228 3 #221 of 228
Profitability 97 #7 of 222 99 #3 of 222 71 #66 of 222
Financial Health 81 #47 of 248 76 #61 of 248 15 #210 of 248
Shareholder Returns 95 #9 of 158 89 #18 of 158 94 #10 of 158
Overall 81 80 51
  • ISRG ranked among 252 companies in Medical Devices and Diagnostics
  • RMD ranked among 252 companies in Medical Devices and Diagnostics
  • SOLV ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodISRGRMDSOLVSPY
1 month +5.6%+1.7%+2.0% -2.0%
3 months +12.4%+6.7%+0.5% -2.8%
6 months +5.3%+18.6%+19.9% +2.0%
Year to date -21.7%-0.6%+12.4% +10.6%
1 year -21.6%-5.0%+18.4% +12.2%
3 years +52.1%+62.6%— +68.1%
3 years, per year +15.0%+17.6%— +18.9%
5 years +25.0%-6.0%— +61.4%
5 years, per year +4.6%-1.2%— +10.1%
10 years +542.1%+300.2%— +248.5%
10 years, per year +20.4%+14.9%— +13.3%

Risk

MeasureISRGRMDSOLVSPY
Volatility, 1Y 36.1%31.1%30.1% 13.6%
Downside volatility, 1Y 38.4%33.9%29.3% 13.9%
Beta vs S&P 500, 1Y 0.920.510.61 1.00
Return / volatility, 1Y -0.60-0.160.61 0.90
Max drawdown, 5Y -49.9%-49.8%-40.0% -25.4%
From 52-week high -25.2%-13.2%-3.7% -3.2%
52-week high $592.85$275.96$92.45 $779.14
52-week low $332.02$182.82$62.49 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleISRGRMDSOLV
P/E now vs peer median 52.4xmedian 26.5x 21.5xmedian 26.5x 97.5xmedian 26.5x
P/S now vs peer median 13.3xmedian 2.7x 5.9xmedian 2.7x 1.9xmedian 2.7x
EV/EBITDA now vs peer median 36.6xmedian 18.4x 15.8xmedian 18.4x 20.3xmedian 18.4x
P/FCF now vs peer median 42.7xmedian 25.4x 20.9xmedian 25.4x 156.0xmedian 25.4x
P/B now vs peer median 9.5xmedian 2.5x 5.7xmedian 2.5x 3.1xmedian 2.5x
PEG now vs peer median 2.04median 0.98 0.99median 0.98 —median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsISRGRMDSOLV
Revenue $11.58B $5.73B $8.16B
Gross profit $7.78B $3.50B $4.47B
Operating income $3.28B $1.89B $454.00M
Net income $2.97B $1.59B $156.00M
Free cash flow $3.60B $1.61B –
R&D $1.49B $393.82M $723.00M
EPS (diluted) $8.41 $11.11 $0.91
Cash & equivalents $2.98B $1.01B $451.00M
Total debt – $409.60M $5.07B
Shares (diluted) 351.60M 143.41M 170.80M
Enterprise value $133.67B $28.67B $12.89B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricISRGRMDSOLV
P/E 52.4x 21.5x 97.5x
P/FCF 42.7x 20.9x 156.0x
P/Operating cash flow 37.6x 19.0x 48.8x
P/S 13.3x 5.9x 1.9x
P/B 9.5x 5.7x 3.1x
P/Tangible book 10.3x 6.1x 6.1x
EV/EBITDA 36.6x 15.8x 20.3x
EV/EBIT 45.6x 17.5x 43.5x
EV/Revenue 12.9x 5.8x 2.4x
EV/FCF 41.6x 20.6x –
EV/Operating cash flow 36.6x 18.7x 63.7x
PEG (3Y EPS CAGR) 2.04 0.99 –

Growth

14 metrics
MetricISRGRMDSOLV
Revenue growth (1Y) 20.5% 9.0% -2.8%
Revenue CAGR (3Y) 19.1% 9.4% –
Gross profit growth (1Y) 21.9% 11.0% -1.6%
Gross profit CAGR (3Y) 19.5% 13.2% –
Operating income growth (1Y) 16.6% 8.5% -79.3%
Operating income CAGR (3Y) 24.8% 18.2% –
Net income growth (1Y) 7.5% 10.8% -89.8%
Net income CAGR (3Y) 24.4% 20.7% –
EPS growth (1Y) 10.8% 13.5% -89.5%
EPS CAGR (3Y) 25.7% 21.8% –
Operating cash flow growth (1Y) 38.1% -6.0% -37.1%
Operating cash flow CAGR (3Y) 26.4% 23.7% –
Free cash flow growth (1Y) 58.4% -9.0% –
Free cash flow CAGR (3Y) 42.0% 25.5% –

Profitability

14 metrics
MetricISRGRMDSOLV
Gross margin 67.2% 61.1% 54.8%
EBITDA margin 35.3% 36.4% 11.9%
Operating margin 28.4% 33.0% 5.6%
Pretax margin 31.3% 35.1% 2.1%
Net margin 25.5% 27.8% 1.9%
FCF margin 31.1% 28.1% –
Operating cash flow margin 35.3% 30.9% 3.8%
Return on equity 17.3% 25.4% 3.3%
Return on assets 14.8% 18.5% 1.1%
Return on invested capital – 22.0% 4.2%
Return on capital employed 18.7% 26.1% 4.3%
Asset turnover 0.6x 0.7x 0.6x
Cash conversion (OCF / net income) 1.4x 1.1x 2.0x
Stock comp / revenue 7.2% 2.0% 2.1%

Financial Health

11 metrics
MetricISRGRMDSOLV
Debt / assets – 5.0% 35.8%
Debt / equity – 0.1x 1.1x
Net debt / EBITDA – -0.3x 4.7x
Debt / FCF – 0.3x –
Liabilities / assets 16.7% 27.6% 66.1%
Equity / assets 83.3% 72.4% 33.9%
Interest coverage – 81.1x –
Current ratio 3.3x 2.6x 1.0x
Quick ratio 2.3x 1.5x 0.5x
Cash ratio 1.6x 0.8x 0.1x
Altman Z-score 30.40 12.00 1.85

Shareholder Returns

7 metrics
MetricISRGRMDSOLV
Dividend yield – 1.1% –
Net buyback yield 2.8% 4.2% 2.7%
Shareholder yield 2.8% 5.3% 2.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusISRGRMDSOLV
Forward P/E 38.5xFY2026 18.5xFY2027 12.8xFY2026
EPS, next fiscal year $11.52FY2026 $12.92FY2027 $6.93FY2026
EPS growth, next FY +29.0%FY2026 +15.7%FY2027 +13.4%FY2026
EPS growth, the year after +4.5% +8.9% +15.3%
Revenue, next fiscal year $11.62BFY2026 $5.99BFY2027 $7.71BFY2026
Revenue growth, next FY +15.5%FY2026 +6.0%FY2027 -7.3%FY2026
Revenue growth, the year after +11.3% -3.8% +5.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersISRGRMDSOLV
Held by institutions 86.2% 68.7% 73.9%
Institutions holding 2,241 889 882
Change in shares held, QoQ +4.6% +3.2% -0.9%
Institutions buying 1,073 404 370
Institutions selling 879 360 286
Buyers to sellers 1.22 1.12 1.29

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ISRGRMDSOLV
ISRG 1.00 0.50 0.35
RMD 0.50 1.00 0.45
SOLV 0.35 0.45 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ISRG, RMD and SOLV?

Intuitive Surgical (ISRG) is the largest by market capitalisation: Intuitive Surgical (ISRG) $153.38B, Resmed (RMD) $34.22B, Solventum (SOLV) $15.18B.

Which stock is cheaper, ISRG, RMD and SOLV?

Resmed (RMD) trades on the lowest price-to-earnings ratio (Intuitive Surgical (ISRG) 51.9x, Resmed (RMD) 21.5x, Solventum (SOLV) 97.3x). On next year's consensus earnings, Solventum (SOLV) is cheapest (Intuitive Surgical (ISRG) 38.5x, Resmed (RMD) 18.5x, Solventum (SOLV) 12.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Intuitive Surgical (ISRG) grew revenue fastest over the trailing twelve months: Intuitive Surgical (ISRG) +20.5%, Resmed (RMD) +9.0%, Solventum (SOLV) -2.8%.

Which company is more profitable?

Resmed (RMD) has the highest net margin (Intuitive Surgical (ISRG) 25.5%, Resmed (RMD) 27.8%, Solventum (SOLV) 1.9%). On return on invested capital, Resmed (RMD) leads (Resmed (RMD) 22.0%, Solventum (SOLV) 4.2%).

Which stock has performed better?

Over the past year Solventum (SOLV) returned the most: Intuitive Surgical (ISRG) -21.6%, Resmed (RMD) -5.0%, Solventum (SOLV) +18.4%. Over five years, Intuitive Surgical (ISRG) compounded fastest (Intuitive Surgical (ISRG) +4.6%/yr, Resmed (RMD) -1.2%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Solventum (SOLV) has been the steadiest (Intuitive Surgical (ISRG) 36.1%, Resmed (RMD) 31.1%, Solventum (SOLV) 30.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ISRG, RMD and SOLV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Intuitive Surgical (ISRG) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.